These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 10798814)
1. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer. Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Solc Z; Huff W; Cantor A; Steele J; Webster C; Donohue M Tech Urol; 2000 Jun; 6(2):128-34. PubMed ID: 10798814 [TBL] [Abstract][Full Text] [Related]
2. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111 [TBL] [Abstract][Full Text] [Related]
3. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R; Steele J; Webster C; Donohue M; Solc Z; Huff W; Cantor A J Endourol; 2000 May; 14(4):343-50. PubMed ID: 10910150 [TBL] [Abstract][Full Text] [Related]
4. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Ko EC; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944 [TBL] [Abstract][Full Text] [Related]
5. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. Sharkey J; Chovnick SD; Behar RJ; Perez R; Otheguy J; Solc Z; Huff W; Cantor A Urology; 1998 May; 51(5):796-803. PubMed ID: 9610594 [TBL] [Abstract][Full Text] [Related]
6. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure. Stock RG; Berkowitz J; Blacksburg SR; Stone NN BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680 [TBL] [Abstract][Full Text] [Related]
10. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy. Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584 [TBL] [Abstract][Full Text] [Related]
11. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671 [TBL] [Abstract][Full Text] [Related]
12. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. Stone NN; Ramin SA; Wesson MF; Stock R; Unger P; Klein G J Urol; 1995 May; 153(5):1555-60. PubMed ID: 7536266 [TBL] [Abstract][Full Text] [Related]
13. Predictors of metastatic disease after prostate brachytherapy. Forsythe K; Burri R; Stone N; Stock RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025 [TBL] [Abstract][Full Text] [Related]
14. Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Schellhammer PF; Moriarty R; Bostwick D; Kuban D Urology; 2000 Sep; 56(3):436-9. PubMed ID: 10962309 [TBL] [Abstract][Full Text] [Related]
15. There is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapy. Herstein A; Wallner K; Merrick G; Orio P; Thornton K; Butler W; Sutlief S Am J Clin Oncol; 2008 Feb; 31(1):6-10. PubMed ID: 18376221 [TBL] [Abstract][Full Text] [Related]
16. Prostate brachytherapy: a descriptive analysis from CaPSURE. Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR; Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105 [TBL] [Abstract][Full Text] [Related]
17. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591 [TBL] [Abstract][Full Text] [Related]
18. The use of transrectal ultrasound placement of radioactive seeds for the definitive treatment of prostate cancer. Zachow SE; Hargis R J Miss State Med Assoc; 1996 Oct; 37(10):771-5. PubMed ID: 8908949 [TBL] [Abstract][Full Text] [Related]
19. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Sharkey J; Cantor A; Solc Z; Huff W; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R Brachytherapy; 2005; 4(1):34-44. PubMed ID: 15737905 [TBL] [Abstract][Full Text] [Related]
20. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]